Flow Cytometry in Oncology and Immunology Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 3.63 Billion
CAGR (2026-2031)	8.25%
Fastest Growing Segment	Software
Largest Market	North America
Market Size (2031)	USD 5.84 Billion

Market Overview

The Global Flow Cytometry in Oncology and Immunology Market is projected to grow from USD 3.63 Billion in 2025 to USD 5.84 Billion by 2031 at a 8.25% CAGR. Flow cytometry in oncology and immunology represents a critical laboratory methodology for the rapid and multiparametric analysis of cell populations, leveraging light scattering and fluorescent properties to characterize cell types, states, and functions. This technology is instrumental in disease diagnosis, prognosis, and therapeutic monitoring within these critical medical fields. Market growth is primarily driven by the increasing global incidence of cancer and immunological disorders, necessitating advanced diagnostic and research tools. Furthermore, escalating research and development investments in personalized medicine and biomarker discovery significantly propel demand, alongside continuous technological advancements enhancing instrument capabilities. According to the International Society for Advancement of Cytometry, their CYTO 2025 annual congress welcomed over 1,600 participants from more than 40 countries, reflecting robust engagement in the field.

A significant challenge impeding market expansion is the substantial capital expenditure required for acquiring advanced flow cytometry instruments and associated reagents. This high initial investment can constrain adoption, particularly for smaller laboratories and healthcare providers in developing regions. Additionally, the need for highly skilled personnel to operate and interpret complex flow cytometry data presents an ongoing operational hurdle for broad implementation.

Key Market Drivers

Expanding applications in oncology research and diagnostics significantly fuels the global flow cytometry market. This technology is indispensable for characterizing cancer cells, monitoring disease progression, and evaluating treatment efficacy, particularly with the proliferation of new therapeutic strategies. The increasing complexity of cancer requires sophisticated tools for biomarker discovery and personalized medicine, making flow cytometry a central component in both research and clinical settings. For instance, according to the American Association for Cancer Research (AACR) Cancer Progress Report 2025, from July 1, 2024, to June 30, 2025, the FDA approved 20 new anticancer therapeutics, alongside new uses for eight previously approved anticancer therapeutics and two new early detection tools. This expansion in approved treatments and diagnostics directly correlates with a heightened demand for flow cytometry to support their development and application.

Simultaneously, technological advancements in flow cytometry platforms are a crucial driver, pushing the boundaries of cellular analysis. Innovations lead to instruments with enhanced capabilities, such as increased parameter detection, improved sensitivity, and more streamlined workflows, addressing the evolving needs of researchers and clinicians. These advancements enable more comprehensive and accurate characterization of cell populations, which is vital for understanding complex immunological responses and diverse cancer phenotypes. For example, according to Beckman Coulter Life Sciences, in March 2025, the company launched the CytoFLEX mosaic Spectral Detection Module, an industry-first modular spectral flow cytometry solution offering up to 88 detection channels. Such innovations foster broader adoption by offering greater insights and operational efficiencies. Furthermore, the commitment to fostering research in these areas is evidenced by significant funding; according to The Mark Foundation for Cancer Research, in March 2026, its flagship Emerging Leader Award program increased its total award for each recipient to $1 million over four years, with global eligibility.

Download Free Sample Report

Key Market Challenges

The significant capital expenditure associated with acquiring advanced flow cytometry instruments and their corresponding reagents represents a considerable impediment to the growth of the Global Flow Cytometry in Oncology and Immunology Market. The initial outlay for these systems can be substantial, encompassing not only the core instrumentation but also necessary accessories, installation, and ongoing maintenance contracts. This financial burden establishes a high entry barrier for many potential adopters.

This elevated upfront investment directly constrains market expansion, particularly affecting smaller laboratories, academic institutions, and healthcare providers in developing economies. Such entities often operate with more restricted budgets, making the acquisition of new, high-cost technology challenging despite its diagnostic and research utility. This limitation curtails the widespread adoption and upgrade cycles of flow cytometry platforms, thereby slowing overall market penetration. According to a TD Securities survey of hospital executives, in 2025, 40% of those surveyed indicated plans to cut or defer capital equipment spending. This demonstrates how financial barriers directly impact the integration of advanced technologies like flow cytometry into routine diagnostic and research workflows within healthcare settings.

Key Market Trends

The increasing adoption of high-throughput and automated systems represents a significant trend in the global flow cytometry in oncology and immunology market, driven by the need for enhanced efficiency and scalability in cellular analysis. These systems streamline complex workflows, minimizing manual intervention and enabling the processing of vastly larger sample volumes. This automation extends from sample preparation to data acquisition, allowing researchers and clinicians to accelerate their studies and diagnostic procedures. For example, according to IntuitionLabs.ai, in April 2026, in the 'Dotmatics Platform & AI Integration in Lab Informatics' report, one customer successfully parsed 42 billion instrument data records from flow cytometry devices in a year using Dotmatics' Luma platform, a volume previously unachievable, demonstrating the sheer data handling capacity such systems facilitate. This increased throughput is critical for large-scale screening, drug discovery, and detailed immune profiling in both research and clinical settings.

Concurrently, the integration of artificial intelligence and advanced data analytics is transforming how insights are extracted from the complex datasets generated by flow cytometry. As the technology yields higher-dimensional data, traditional manual analysis methods become increasingly insufficient. AI and machine learning algorithms offer sophisticated tools for automated cell population identification, anomaly detection, and biomarker discovery, enhancing the depth and speed of interpretation. This allows for more precise characterization of disease states and treatment responses, moving beyond basic phenotyping to predictive analytics. According to Menlo Ventures, in October 2025, their research indicated that 22% of healthcare organizations had implemented domain-specific AI tools, highlighting a growing acceptance and integration of advanced analytical capabilities within the broader healthcare sector, which directly influences the application of AI in flow cytometry data interpretation for oncology and immunology.

Segmental Insights

In the Global Flow Cytometry in Oncology and Immunology Market, Software emerges as the fastest-growing segment, driven by its pivotal role in advancing research and clinical applications. This rapid expansion is primarily attributed to the increasing demand for sophisticated data analysis and interpretation capabilities, essential for complex cellular profiling in cancer and immune-related disorders. Software solutions, increasingly integrated with artificial intelligence and machine learning, enable automated population identification, biomarker discovery, and real-time quality control, thereby enhancing analytical precision and reproducibility. Furthermore, the shift towards precision medicine and personalized therapeutic strategies in oncology and immunology necessitates advanced software for detailed cell-level insights and the development of tailored treatment approaches. These technological advancements significantly improve research efficiency and diagnostic accuracy.

Regional Insights

North America emerges as the leading region in the Global Flow Cytometry in Oncology and Immunology Market, primarily driven by its robust healthcare infrastructure and substantial research and development investments within the biotechnology and pharmaceutical sectors. The high prevalence of chronic diseases, including various cancers and autoimmune disorders, significantly increases the demand for advanced diagnostic and monitoring technologies. This demand, coupled with continuous technological advancements and rapid adoption of innovative flow cytometry solutions, establishes North America's market dominance. Regulatory bodies such as the U.S. Food and Drug Administration play a crucial role by providing oversight and guidelines for flow cytometry applications, further solidifying the region's prominent position.

Recent Developments

In April 2026, Tempus and Predicta Biosciences announced the commercial expansion of their co-branded whole-genome sequencing assay, GenoPredicta™. This ultrasensitive assay is designed for the comprehensive genomic characterization of hematologic malignancies and measurable residual disease (MRD) monitoring. Notably, it integrates flow cytometry for precise tumor cell detection and enumeration, allowing for deep genetic insights from peripheral blood or bone marrow samples. This collaboration aims to provide enhanced sensitivity and clarity to researchers, enabling earlier detection and more informed treatment decisions in oncology.
In March 2026, Biotium released its ViaPlex™ 2-Color Cell Barcoding Kit, a new product designed to streamline flow cytometry workflows. This kit facilitates the fluorescent barcoding of up to 15 distinct cell populations in a single tube, allowing for multiplex analysis. The innovation significantly reduces reagent consumption and sample running time, thereby increasing throughput for various research applications in immunology and oncology. The ViaPlex™ kit enhances efficiency and consistency in cellular screening, which is beneficial for drug discovery and other high-throughput experimental workflows.
In December 2025, BD (Becton, Dickinson and Company) announced a strategic collaboration with the University of Pennsylvania's Institute for Immunology and Immune Health. This partnership aimed to advance research in deep human immune profiling and support the development of immune-mediated therapies through enhanced flow cytometry capabilities. The collaboration focused on developing and validating a high-parameter flow cytometry panel capable of capturing key functional pathways in whole blood, including phosphorylation markers. This effort was intended to provide deeper insights into how single cells respond to various drugs or disease states, supporting a planned 1,000-patient immune profiling study.
In December 2025, TD2 Oncology expanded its specialized flow cytometry services by launching new panels tailored for in vivo CAR-T cell treatments. This development directly addressed the evolving needs in oncology and autoimmune disease research by enabling high-resolution monitoring of CAR-T cell dynamics. The new flow cytometry assays were designed to track CAR-T persistence, activation, and efficacy, providing crucial data for preclinical models and clinical trials. This expansion supports the advancement of next-generation in vivo CAR therapies, ensuring more reliable and faster data to accelerate therapeutic development.

Key Market Players

Agilent Technologies, Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Cell Signaling Technology, Inc.
Cytek Biosciences, Inc.
Danaher Corporation
DiaSorin S.p.A.
Enzi Biochem Inc.
Laboratory Corporation of America Holdings
Merck KGaA

By Type	By Technology	By Offering	By Application	By End User	By Region
Immunology Oncology	Cell-based flow cytometry Bead-based Flow Cytometry	Reagents Instruments Consumables Software	Translational Research Clinical Research	Hospitals Diagnostic Laboratories and Reference Laboratories Pharmaceutical and Biotechnology Companies Academic Research Institutes Contract Research Organizations Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Flow Cytometry in Oncology and Immunology Market, By Type:

Immunology
Oncology

Flow Cytometry in Oncology and Immunology Market, By Technology:

Cell-based flow cytometry
Bead-based Flow Cytometry

Flow Cytometry in Oncology and Immunology Market, By Offering:

Reagents
Instruments
Consumables Software

Flow Cytometry in Oncology and Immunology Market, By Application:

Translational Research
Clinical Research

Flow Cytometry in Oncology and Immunology Market, By End User:

Hospitals
Diagnostic Laboratories
and Reference Laboratories
Pharmaceutical and Biotechnology Companies
Academic Research Institutes
Contract Research Organizations
Others

Flow Cytometry in Oncology and Immunology Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Flow Cytometry in Oncology and Immunology Market.

Available Customizations:

Global Flow Cytometry in Oncology and Immunology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Flow Cytometry in Oncology and Immunology Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Cytometry in Oncology and Immunology Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Type (Immunology, Oncology)

5.2.2. By Technology (Cell-based flow cytometry, Bead-based Flow Cytometry)

5.2.3. By Offering (Reagents, Instruments, Consumables Software)

5.2.4. By Application (Translational Research, Clinical Research)

5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, Others)

5.2.6. By Region

5.2.7. By Company (2025)

5.3. Market Map

6. North America Flow Cytometry in Oncology and Immunology Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type

6.2.2. By Technology

6.2.3. By Offering

6.2.4. By Application

6.2.5. By End User

6.2.6. By Country

6.3. North America: Country Analysis

6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Type

6.3.1.2.2. By Technology

6.3.1.2.3. By Offering

6.3.1.2.4. By Application

6.3.1.2.5. By End User

6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Type

6.3.2.2.2. By Technology

6.3.2.2.3. By Offering

6.3.2.2.4. By Application

6.3.2.2.5. By End User

6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Type

6.3.3.2.2. By Technology

6.3.3.2.3. By Offering

6.3.3.2.4. By Application

6.3.3.2.5. By End User

7. Europe Flow Cytometry in Oncology and Immunology Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type

7.2.2. By Technology

7.2.3. By Offering

7.2.4. By Application

7.2.5. By End User

7.2.6. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type

7.3.1.2.2. By Technology

7.3.1.2.3. By Offering

7.3.1.2.4. By Application

7.3.1.2.5. By End User

7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type

7.3.2.2.2. By Technology

7.3.2.2.3. By Offering

7.3.2.2.4. By Application

7.3.2.2.5. By End User

7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type

7.3.3.2.2. By Technology

7.3.3.2.3. By Offering

7.3.3.2.4. By Application

7.3.3.2.5. By End User

7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Type

7.3.4.2.2. By Technology

7.3.4.2.3. By Offering

7.3.4.2.4. By Application

7.3.4.2.5. By End User

7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Type

7.3.5.2.2. By Technology

7.3.5.2.3. By Offering

7.3.5.2.4. By Application

7.3.5.2.5. By End User

8. Asia Pacific Flow Cytometry in Oncology and Immunology Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type

8.2.2. By Technology

8.2.3. By Offering

8.2.4. By Application

8.2.5. By End User

8.2.6. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Type

8.3.1.2.2. By Technology

8.3.1.2.3. By Offering

8.3.1.2.4. By Application

8.3.1.2.5. By End User

8.3.2. India Flow Cytometry in Oncology and Immunology Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Type

8.3.2.2.2. By Technology

8.3.2.2.3. By Offering

8.3.2.2.4. By Application

8.3.2.2.5. By End User

8.3.3. Japan Flow Cytometry in Oncology and Immunology Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Type

8.3.3.2.2. By Technology

8.3.3.2.3. By Offering

8.3.3.2.4. By Application

8.3.3.2.5. By End User

8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Type

8.3.4.2.2. By Technology

8.3.4.2.3. By Offering

8.3.4.2.4. By Application

8.3.4.2.5. By End User

8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Type

8.3.5.2.2. By Technology

8.3.5.2.3. By Offering

8.3.5.2.4. By Application

8.3.5.2.5. By End User

9. Middle East & Africa Flow Cytometry in Oncology and Immunology Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type

9.2.2. By Technology

9.2.3. By Offering

9.2.4. By Application

9.2.5. By End User

9.2.6. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Type

9.3.1.2.2. By Technology

9.3.1.2.3. By Offering

9.3.1.2.4. By Application

9.3.1.2.5. By End User

9.3.2. UAE Flow Cytometry in Oncology and Immunology Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Type

9.3.2.2.2. By Technology

9.3.2.2.3. By Offering

9.3.2.2.4. By Application

9.3.2.2.5. By End User

9.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Type

9.3.3.2.2. By Technology

9.3.3.2.3. By Offering

9.3.3.2.4. By Application

9.3.3.2.5. By End User

10. South America Flow Cytometry in Oncology and Immunology Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Type

10.2.2. By Technology

10.2.3. By Offering

10.2.4. By Application

10.2.5. By End User

10.2.6. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Type

10.3.1.2.2. By Technology

10.3.1.2.3. By Offering

10.3.1.2.4. By Application

10.3.1.2.5. By End User

10.3.2. Colombia Flow Cytometry in Oncology and Immunology Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Type

10.3.2.2.2. By Technology

10.3.2.2.3. By Offering

10.3.2.2.4. By Application

10.3.2.2.5. By End User

10.3.3. Argentina Flow Cytometry in Oncology and Immunology Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Type

10.3.3.2.2. By Technology

10.3.3.2.3. By Offering

10.3.3.2.4. By Application

10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Flow Cytometry in Oncology and Immunology Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Agilent Technologies, Inc.

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Becton, Dickinson and Company

15.3. Bio-Rad Laboratories, Inc.

15.4. Cell Signaling Technology, Inc.

15.5. Cytek Biosciences, Inc.

15.6. Danaher Corporation

15.7. DiaSorin S.p.A.

15.8. Enzi Biochem Inc.

15.9. Laboratory Corporation of America Holdings

15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Flow Cytometry in Oncology and Immunology Market in 2025?

Which is the dominating region in the Global Flow Cytometry in Oncology and Immunology Market?

Which is the fastest growing segment in the Global Flow Cytometry in Oncology and Immunology Market?

What is the expected growth rate of the Global Flow Cytometry in Oncology and Immunology Market?